Article Text

Download PDFPDF

PR064/#206  Multicenter real-world experiences of PARPi rechallenge in patients with ovarian cancer in China
  1. Jin Li1,
  2. Feng Shao2,
  3. Lingjun Zhao3,
  4. Fei Zheng4,
  5. Hua Zhu5,
  6. Enchun Li6,
  7. Wei Zhou7,
  8. Guorong Yao8,
  9. Jie Liu9,
  10. Jianxiao Zheng10,
  11. Shan Pan11,
  12. Yue Zhang12 and
  13. Xiaohua Wu1
  1. 1Fudan University Shanghai Cancer Center, Department of Gynecologic Oncology, Shanghai, China
  2. 2Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Gynecologic Surgical Department, Hangzhou, China
  3. 3Ningbo Women and Children’s Hospital, Department of Gynecology, Ningbo, China
  4. 4Ningbo No.2 Hospital, Department of Gynecology, Ningbo, China
  5. 5The First Affiliated Hospital of Wenzhou Medical University, Department of Gynecology, WenZhou, China
  6. 6Women’s Hospital School of Medicine Zhejiang University, Department of Gynecology, Hangzhou, China
  7. 7Taizhou Hospital of Zhejiang Province, Department of Gynecology, Taizhou, China
  8. 8Huzhou Central Hospital, Department of Integrated Chinese and Western Medicine, Huzhou, China
  9. 9Jinhua People’s Hospital, Department of Gynecology, Jinhua, China
  10. 10Yueqing People’s Hospital, Department of Integrated Chinese and Western Medicine, Wenzhou, China
  11. 11Jiaxing University Affiliated Women and Children Hospital, Department of Gynecology, Jiaxing, China
  12. 12The First Affiliated Hospital, Zhejiang University School of Medicine, Department of Gynecology, Hangzhou, China


Introduction The OReO/ENGOT Ov-38 trial showed maintenance olaparib rechallenge improved progression-free survival (PFS) compared with placebo. However, subpopulation benefit more from Poly (ADP-ribose) polymerase inhibitors (PARPi) rechallenge was unclear. The objective of this real-world study is to evaluate the effectiveness, safety and explore benefit population of PARPi rechallenge in China.

Methods This multi-center, non-interventional study included patients with PARPi-treated recurrent ovarian cancer who rechallenged PARPi as maintenance therapy or salvage treatment at 12 institutions between June 2019 and March 2023. Patients‘ demographics and outcomes were analyzed.

Results Seventy patients were included, and the median follow-up time was 13.0 months. Fifty-six (80%, 56/70) patients received PARPi as maintenance after maintenance therapy (table 1). The median PFS (mPFS) was 10.6 months (95% confidence interval [CI], 7.1–12.0) with first PARPi (PARPi1) and 8.6 months (95% CI, 5.3–13.0) with PARPi retreatment (PARPi2) (figure 1). 32.1%(18/56) patients were BRCA1/2 mutated, the PFS were not significantly different from BRCA wild-type or unknown patients (BRCAm vs. BRCAwt or unknown, HR=0.997 [95%CI: 0.480–2.072], P=0.9935). 87.5% (39/56) of patients switched to other PARPi when rechallenging. Patients switched to other PARPi rechallenging had numerically longer mPFS compared with those didn’t switch (mPFS: 8.6 vs. 7.7 months; HR=0.820 [95%CI: 0.394–1.707], P=0.5958). Overall, 4.3% (3/70) discontinued PARPi2 due to adverse events, most commonly due to hematologic adverse events.

Conclusion/Implications Our study is the first multicenter real-world study to evaluate the rechallenge of PARPi in ovarian cancer patients in China. There is a pressing need to identify the biomarkers except BRCA to select appropriate patients for PARPi rechallenge.

Abstract PR064/#206 Table 1
Abstract PR064/#206 Figure 1

Kaplan-Meier plot of progression-free survival of patients receiving PARPi2 as maintenance therapy after PARPi1 maintenance therapy (N=56)

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.